Alnylam Pharmaceuticals EPS Non-GAAP de US$ 16,26 supera em US$ 14,01, receita de US$ 1,46 bi supera em US$ 30 mi

Alnylam Pharmaceuticals Q3 earnings surged on strong revenue and a major EPS beat.

CryptoAlerta — análise de criptomoedas e mercado em tempo real